Larotrectinib OK'd for Cancers With TRK Fusions

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2018-163
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Larotrectinib Has Antitumor Activity in TRK + Pediatric Solid Tumors

Cancer Discovery
Oncology
2018English

Abstract P6-20-02: Activity of Larotrectinib, a Highly Selective Inhibitor of Tropomyosin Receptor Kinase, in TRK Fusion Breast Cancers

2019English

Off-Target Alterations Drive Resistance to TRK Inhibitors in Some Cancers

Cancer Discovery
Oncology
2019English

First-Line Atezolizumab OK'd for SCLC

Cancer Discovery
Oncology
2019English

Mast and Notch Fusions Drive a Subset of Breast Cancers

Cancer Discovery
Oncology
2011English

Abstract PR07: A Pediatric Phase 1 Study of Larotrectinib, a Highly Selective Inhibitor of the Tropomyosin Receptor Kinase (TRK) Family: An Updated Analysis

2018English

Selective TRK Inhibitor CH7057288 Against TRK Fusion-Driven Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Methods for Identifying Patients With Tropomyosin Receptor Kinase (TRK) Fusion Cancer

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2019English

Tumor-Agnostic Therapy Gets on TRK

Science
MultidisciplinaryPhilosophy of ScienceHistory
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy